Orion Corporation, Orion Pharma — CureCurrent

Published trials65

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

A 2-part Phase 1/2 Open-label Trial on ODM-212NCT07563738 · lead sponsor · 2026-03-27

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge TestingNCT05084222 · lead sponsor · 2021-11-11

Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With AsthmaNCT04869384 · lead sponsor · 2021-06-23

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in NorwayNCT04663386 · lead sponsor · 2020-12-10

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHalerNCT04147572 · lead sponsor · 2019-11-01

Safety and Pharmacokinetics of ODM-209NCT03878823 · lead sponsor · 2019-04-17

Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPDNCT03755544 · lead sponsor · 2019-01-16

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerNCT03436485 · lead sponsor · 2018-03-19

ACTIVE_NOT_RECRUITING

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)NCT03238482 · lead sponsor · 2017-08-16

Pharmacokinetic of Levodopa Study in Healthy MalesNCT03140956 · lead sponsor · 2017-04-19

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide DiskusNCT03060044 · lead sponsor · 2016-07-01

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)NCT02764125 · lead sponsor · 2016-04-08

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort TurbuhalerNCT03073057 · lead sponsor · 2016-01-01

Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's DiseaseNCT02471196 · lead sponsor · 2015-08-14

Pharmacokinetic Study in Healthy VolunteersNCT02554734 · lead sponsor · 2015-08-01

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate CancerNCT02344017 · lead sponsor · 2015-02-01

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference ProductNCT02308098 · lead sponsor · 2014-12-01

Pharmacokinetic Study in Healthy MalesNCT02312232 · lead sponsor · 2014-11-01

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide DiskusNCT02162485 · lead sponsor · 2014-06-01

Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide DiskusNCT01856621 · lead sponsor · 2013-05-01

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate CancerNCT01784757 · lead sponsor · 2013-03-01

Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide DiskusNCT01766843 · lead sponsor · 2013-01-01

Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at HomeNCT01783132 · lead sponsor · 2012-12-01

Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder InhalersNCT01668121 · lead sponsor · 2012-08-01

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler ForteNCT01627158 · lead sponsor · 2012-06-01

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort TurbuhalerNCT01593826 · lead sponsor · 2012-05-01

Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)NCT01424137 · lead sponsor · 2011-09-01

Phase I Pharmacokinetic Study (BF-BLOCK)NCT01423305 · lead sponsor · 2011-08-01

Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort TurbuhalerNCT01386996 · lead sponsor · 2011-07-01

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001NCT01429064 · lead sponsor · 2011-06-01

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsNCT01766258 · lead sponsor · 2011-05-01

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's DiseaseNCT01324518 · lead sponsor · 2011-04-01

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate CancerNCT01317641 · lead sponsor · 2011-03-01

Comparing Different Levodopa/Carbidopa/Entacapone Treatment RegimensNCT01296464 · lead sponsor · 2011-02-01

Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate CancerNCT01574846 · lead sponsor · 2011-01-01

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder InhalersNCT01181063 · lead sponsor · 2010-08-01

Levodopa Concentration Profile With Stalevo 75/125 mgNCT01070628 · lead sponsor · 2009-12-01

Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler InhalersNCT00984906 · lead sponsor · 2009-09-01

Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in AsthmaticsNCT00964535 · lead sponsor · 2009-09-01

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride BindingNCT00562198 · lead sponsor · 2008-01-01

Study to Evaluate Initiation of Stalevo in Early Wearing-offNCT00462007 · lead sponsor · 2006-09-01

Stalevo in Early Wearing-Off PatientsNCT00125567 · lead sponsor · 2005-08-01

Peroral Levosimendan in Chronic Heart FailureNCT00130884 · lead sponsor · 2005-03-01

Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.NCT00247247 · lead sponsor · 2002-12-01

Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.NCT00219388 · lead sponsor · 2002-11-01

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · collaborator · 2024-05-20

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)NCT06566989 · collaborator · 2024-09-19

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)NCT06136598 · collaborator · 2024-01-30

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)NCT06104449 · collaborator · 2023-11-14

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerNCT04736199 · collaborator · 2021-02-23

Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart FailureNCT03576677 · collaborator · 2019-08-01

Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart FailureNCT03437226 · collaborator · 2018-03-08

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male VolunteersNCT03237416 · collaborator · 2017-08-02

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · collaborator · 2016-11-30

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · collaborator · 2014-09-12

Preoperative levosimendán and Hip FractureNCT02972918 · collaborator · 2014-05-01

Levosimendan Pharmacokinetics in ChildrenNCT01704131 · collaborator · 2012-11-01

Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)NCT02261948 · collaborator · 2012-09-01

Real Life Effectiveness of Easyhaler (Orion)NCT02048930 · collaborator · 2012-09-01

Preoperative Levosimendan and Heart FailureNCT01022983 · collaborator · 2011-04-01

Sponsor roles

lead sponsor45

collaborator20

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.